Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Berg

Showing results (371-380 of 547) with videos related to

Pageof 55
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|September 30, 2025
Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused UltrasoundJustina Dargvainiene, Ann-Kristin Helmers, Juliana Naumann, et al.
Neurology|November 21, 2020
Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without DementiaSara Becker, Oliver Granert, Maarten Timmers, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 6, 2014
Hand function is impaired in healthy older adults at risk of Parkinson's diseaseGabrielle Todd, Miranda Haberfield, Patrick L Faulkner, et al.
Brain : a Journal of Neurology|November 22, 2012
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayKinnari Sathe, Walter Maetzler, Johannes D Lang, et al.
Neurobiology of Disease|February 28, 2016
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinMatteo Santoro, Walter Maetzler, Petros Stathakos, et al.
Plos One|March 4, 2016
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body DementiaWalter Maetzler, Willy Deleersnijder, Valérie Hanssens, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
Age- and sex-related heterogeneity in prodromal Parkinson's diseaseSebastian Heinzel, Meike Kasten, Stefanie Behnke, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 27, 2018
Parkinson's disease: evolution of cognitive impairment and CSF Aβ<sub>1-42</sub> profiles in a prospective longitudinal studyStefanie Lerche, Isabel Wurster, Benjamin Röben, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 23, 2018
Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's diseaseStefanie Lerche, Inga Liepelt-Scarfone, Isabel Wurster, et al.
NPJ Parkinson'S Disease|March 19, 2024
Turning alterations detected by mobile health technology in idiopathic REM sleep behavior disorderCinzia Zatti, Andrea Pilotto, Clint Hansen, et al.
Pageof 55

Showing results (371-380 of 547) with videos related to

Sort By:
Pageof 55
Movement Disorders : Official Journal of the Movement Disorder Society|September 30, 2025
Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused UltrasoundJustina Dargvainiene, Ann-Kristin Helmers, Juliana Naumann, et al.
Neurology|November 21, 2020
Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without DementiaSara Becker, Oliver Granert, Maarten Timmers, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 6, 2014
Hand function is impaired in healthy older adults at risk of Parkinson's diseaseGabrielle Todd, Miranda Haberfield, Patrick L Faulkner, et al.
Brain : a Journal of Neurology|November 22, 2012
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayKinnari Sathe, Walter Maetzler, Johannes D Lang, et al.
Neurobiology of Disease|February 28, 2016
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinMatteo Santoro, Walter Maetzler, Petros Stathakos, et al.
Plos One|March 4, 2016
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body DementiaWalter Maetzler, Willy Deleersnijder, Valérie Hanssens, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
Age- and sex-related heterogeneity in prodromal Parkinson's diseaseSebastian Heinzel, Meike Kasten, Stefanie Behnke, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 27, 2018
Parkinson's disease: evolution of cognitive impairment and CSF Aβ<sub>1-42</sub> profiles in a prospective longitudinal studyStefanie Lerche, Isabel Wurster, Benjamin Röben, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 23, 2018
Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's diseaseStefanie Lerche, Inga Liepelt-Scarfone, Isabel Wurster, et al.
NPJ Parkinson'S Disease|March 19, 2024
Turning alterations detected by mobile health technology in idiopathic REM sleep behavior disorderCinzia Zatti, Andrea Pilotto, Clint Hansen, et al.
Pageof 55